24.06.2015 • NewsDede WillamsVaccinesPfizer

Pfizer to Acquire Meningitis Vaccines From GSK

© frauunhold - Fotolia.com
© frauunhold - Fotolia.com

Pfizer has agreed to acquire the quadrivalent meningitis ACWY vaccines Nimenrix and Mencevax from GlaxoSmithKline (GSK) for €115 million. The deal, expected to close in the second half of 2015 following all approvals will add two complementary vaccines to the US drugmaker’s portfolio, “allowing us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need,” said Susan Silbermann, president of Pfizer Vaccines.

Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine), launched by GSK three years ago, is a single dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitides. It is currently registered and approved for sale in 61 countries across the European Economic Area, Canada, Australia and emerging market with further registrations under review.

Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine),a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection, is currently registered and approved in 79 countries across Africa, Asia, Australia, Europe, Latin America, the Middle East and New Zealand.

Pfizer said its vaccine strategy includes growing its core business, advancing its pipeline and enhancing its portfolio through targeted external opportunities that complement its existing products and future pipeline.

The company does not expect the deal with GSK to have any significant impact on its 2015 financial performance.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.